Abstract:ABSTRACT The incidence of isoniazid (INH) resistant Mycobacterium tuberculosis is increasing globally. This study aimed to identify the molecular mechanisms behind the development of INH resistance in M. tuberculosis strains collected from the same patients during the standard course of treatment. Three M. tuberculosis strains were collected from a patient before and during antituberculosis (anti-TB) therapy. The strains were characterized using phenotypic drug susceptibility tests, Mycobacterial Interspersed Repeated Unit-Variable-Number Tandem Repeats (MIRU-VNTR), and whole-genome sequencing (WGS) to identify mutations associated with INH resistance. To validate the role of the novel mutations in INH resistance, the mutated katG genes were electroporated into a KatG-deleted M. tuberculosis strain (GA03). Three-dimensional structures of mutated KatG were modeled to predict their impact on INH binding. The pre-treatment strain was susceptible to INH. However, two INH-resistant strains were isolated from the patient after anti-TB therapy. MIRU-VNTR and WGS revealed that the three strains were clonally identical. A missense mutation (P232L) and a nonsense mutation (Q461Stop) were identified in the katG of the two post-treatment strains, respectively. Transformation experiments showed that katG of the pre-treatment strain restored INH susceptibility in GA03, whereas the mutated katG genes from the post-treatment strains rendered negative catalase activity and INH resistance. The protein model indicated that P232L reduced INH-KatG binding affinity while Q461Stop truncated gene transcription. Our results showed that the two katG mutations, P232L and Q461Stop, accounted for the co-emergence of INH-resistant clones during anti-TB therapy. The inclusion of these mutations in the design of molecular assays could increase the diagnostic performance. IMPORTANCE The evolution of drug-resistant strains of Mycobacterium tuberculosis within the lung lesions of a patient has a detrimental impact on treatment outcomes. This is particularly concerning for isoniazid (INH), which is the most potent first-line antimycobacterial drug. However, the precise genetic factors responsible for drug resistance in patients have not been fully elucidated, with approximately 15% of INH-resistant strains harboring unknown genetic factors. This raises concerns about the emergence of drug-resistant clones within patients, further contributing to the global epidemic of resistance. In this study, we revealed the presence of two novel katG mutations, which emerged independently due to the stress exerted by antituberculosis (anti-TB) treatment on a parental strain. Importantly, we experimentally demonstrated the functional significance of both mutations in conferring resistance to INH. Overall, this research sheds light on the genetic mechanisms underlying the evolution of INH resistance within patients and provides valuable insights for improving diagnostic performance by targeting specific mutations.

Molecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis

Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India

Detection of Rifampicin-Resistance Mutations in Mycobacterium Tuberculosis

Drug Resistance-Related Mutations in Multidrug-Resistant Mycobacterium Tuberculosis Isolates from Diverse Geographical Regions.

Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis

Mutations in Dnaa and a Cryptic Interaction Site Increase Drug Resistance in Mycobacterium Tuberculosis.

Mycobacterium Tuberculosis Carrying a Rifampicin Drug Resistance Mutation Reprograms Macrophage Metabolism Through Cell Wall Lipid Changes

Genome-wide SNP and InDel Mutations in Mycobacterium Tuberculosis Associated with Rifampicin and Isoniazid Resistance.

Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex

Identification of drug resistance-related virulence gene mutations in 667 clinical Mycobacterium tuberculosis isolates

A Systematic Review of Mutations Associated with Isoniazid Resistance Points to Lower Diagnostic Sensitivity for Common Mutations and Increased Incidence of Uncommon Mutations in Clinical Strains of Mycobacterium tuberculosis

Identification of gene targets that potentiate the action of rifampicin on Mycobacterium bovis BCG

Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis

Identification of Novel Mutations Associated with Cycloserine Resistance Inmycobacterium Tuberculosis

Mutation of Rifampicin-resistant Genes in M.tuberculosis with Gene Chip

Comparative Genomic Analysis of Two Clonally Related Multidrug Resistant Mycobacterium tuberculosis by Single Molecule Real Time Sequencing

Genome-wide DNA Methylation and Transcriptome Changes in Mycobacterium Tuberculosis with Rifampicin and Isoniazid Resistance.

Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

Molecular Detection of Isoniazid, Rifampin and Ethambutol Resistance to M. Tuberculosis and M. Bovis in Multidrug Resistant Tuberculosis (MDR-TB) Patients in Pakistan.

Genetic mechanisms of co-emergence of INH-resistant Mycobacterium tuberculosis strains during the standard course of antituberculosis therapy

Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons